(ARVN) Arvinas - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US04335A1051
ARVN: Protein, Degraders, Cancer, Breast, Prostate
Arvinas, Inc. is a clinical-stage biotech company pioneering a novel approach to treating diseases by targeting and degrading proteins that cause harm. Their platform centers around PROTACs—proteolysis-targeting chimeras—which hijack the cells natural protein disposal system to eliminate disease-causing proteins. This is a significant shift from traditional drug development, which often focuses on inhibiting or blocking proteins rather than removing them entirely.
Their pipeline is focused on cancer, with three lead programs. Bavdegalutamide and ARV-766 are oral PROTACs targeting metastatic castration-resistant prostate cancer, a condition where prostate cancer grows despite hormone therapies. Both are in Phase 1/2 trials, aiming to show safety and efficacy. ARV-471 is further along, in Phase 3 trials, for estrogen receptor-positive breast cancer. This drug targets the estrogen receptor, a key driver in many breast cancers.
Collaborations are a key part of their strategy. Partnerships with pharma giants like Pfizer, Genentech, Roche, Bayer, and Carrick Therapeutics provide validation and resources. These deals not only bring in capital but also leverage the expertise and infrastructure of larger companies, reducing some of the risks in drug development.
As a public company on NASDAQ (ticker: ARVN), Arvinas has a market cap of ~$1.28 billion. Their financials reflect a typical clinical-stage biotech: no earnings yet, with a forward P/E of 17.7 and a price-to-book ratio of 2.19. The price-to-sales ratio is 7.98, reflecting the premium investors place on their pipeline and technology. Founded in 2013 and based in New Haven, Connecticut, Arvinas is at the forefront of the PROTAC revolution in drug discovery.
Additional Sources for ARVN Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ARVN Stock Overview
Market Cap in USD | 1,242m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2018-09-27 |
ARVN Stock Ratings
Growth 5y | -77.0% |
Fundamental | -31.1% |
Dividend | 0.0% |
Rel. Strength Industry | -81.3 |
Analysts | 4.59/5 |
Fair Price Momentum | 7.09 USD |
Fair Price DCF | - |
ARVN Dividends
No Dividends PaidARVN Growth Ratios
Growth Correlation 3m | -67.8% |
Growth Correlation 12m | -87.5% |
Growth Correlation 5y | -52.9% |
CAGR 5y | -23.85% |
CAGR/Max DD 5y | -0.26 |
Sharpe Ratio 12m | -1.31 |
Alpha | -95.86 |
Beta | 1.62 |
Volatility | 210.25% |
Current Volume | 2202.4k |
Average Volume 20d | 1500.2k |
As of March 15, 2025, the stock is trading at USD 8.43 with a total of 2,202,370 shares traded.
Over the past week, the price has changed by -53.88%, over one month by -53.96%, over three months by -55.61% and over the past year by -81.15%.
Probably not. Based on ValueRay Fundamental Analyses, Arvinas (NASDAQ:ARVN) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -31.05 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ARVN as of March 2025 is 7.09. This means that ARVN is currently overvalued and has a potential downside of -15.9%.
Arvinas has received a consensus analysts rating of 4.59. Therefor, it is recommend to buy ARVN.
- Strong Buy: 15
- Buy: 5
- Hold: 2
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, ARVN Arvinas will be worth about 7.9 in March 2026. The stock is currently trading at 8.43. This means that the stock has a potential downside of -6.52%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 60.7 | 620% |
Analysts Target Price | 63.4 | 652.3% |
ValueRay Target Price | 7.9 | -6.5% |